Cargando…

“Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)"

The sudden increase in the COVID-19 epidemic affected by novel coronavirus 2019 has jeopardized public health worldwide. Hence the necessities of a drug or therapeutic agent that heal SARS-CoV-2 infections are essential requirements. The viral genome encodes a large Polyprotein, further processed by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhowmik, Deep, Sharma, Ravi Datta, Prakash, Amresh, Kumar, Diwakar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884051/ https://www.ncbi.nlm.nih.gov/pubmed/33612858 http://dx.doi.org/10.1016/j.molstruc.2021.130094

Ejemplares similares

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

An overview of potential inhibitors targeting non-structural proteins 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2
por: Yan, Fangfang, et al.
Publicado: (2021)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis
por: Bhowmik, Deep, et al.
Publicado: (2021)

Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A novel structure-based design approach to treat COVID-19
por: Rajpoot, Sajjan, et al.
Publicado: (2020)

Effects of diarylbutane lignans from Schisandra chinensis fruit on SARS-CoV-2 3CL(pro) and PL(pro) and their in vitro anti-inflammatory properties
por: Li, Bin, et al.
Publicado: (2023)

3CL(pro) and PL(pro) affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?
por: Štekláč, Marek, et al.
Publicado: (2021)

Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches
por: Bhowmik, Deep, et al.
Publicado: (2020)

Schaftoside inhibits 3CL(pro) and PL(pro) of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
por: Yi, Yang, et al.
Publicado: (2022)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CL(pro) and PL(pro)
por: Nagahawatta, D. P., et al.
Publicado: (2022)

Nafamostat has anti-asthmatic effects associated with suppressed pro-inflammatory gene expression, eosinophil infiltration and airway hyperreactivity
por: Allam, Venkata Sita Rama Raju, et al.
Publicado: (2023)

Spatial and temporal roles of SARS‐CoV PL(pro)—A snapshot
por: Yan, Shaomin, et al.
Publicado: (2020)

SARS-CoV-PL(pro)-Inhibitoren als mögliche Breitspektrum-Virostatika
por: Hammerschmidt, Stefan Josef, et al.
Publicado: (2021)

In silico study of natural compounds from sesame against COVID-19 by targeting M(pro), PL(pro) and RdRp
por: Allam, Ahmed E., et al.
Publicado: (2021)

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M(Pro) and PL(Pro)
por: Kattula, Bhavita, et al.
Publicado: (2023)

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)
por: Tan, Haozhou, et al.
Publicado: (2023)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

In Silico and In Vitro Inhibition of SARS-CoV-2 PL(pro) with Gramicidin D
por: Protić, Sara, et al.
Publicado: (2023)

Pro-resolving and anti-arthritic properties of the MC(1) selective agonist PL8177
por: Garrido-Mesa, Jose, et al.
Publicado: (2022)

Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2)
por: Mouffouk, Chaima, et al.
Publicado: (2021)

In silico studies of M(pro) and PL(pro) from SARS-CoV-2 and a new class of cephalosporin drugs containing 1,2,4-thiadiazole
por: Delgado, Cássia Pereira, et al.
Publicado: (2022)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

Crystal structure of nafamostat dimesylate
por: Fujii, Isao
Publicado: (2021)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Molecular dissection of resistance gene cluster and candidate gene identification of Pl(17) and Pl(19) in sunflower by whole-genome resequencing
por: Ma, Guojia, et al.
Publicado: (2019)

Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2
por: Gao, Hongwei, et al.
Publicado: (2023)

MERS‐CoV papain-like protease (PL(pro)): expression, purification, and spectroscopic/thermodynamic characterization
por: Malik, Ajamaluddin, et al.
Publicado: (2017)

Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 M(Pro) and PL(Pro)
por: Mousavi, Hossein, et al.
Publicado: (2023)

Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates
por: Chitranshi, Nitin, et al.
Publicado: (2020)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Engineering a novel endopeptidase based on SARS 3CL(pro)
por: Kuo, Chih-Jung, et al.
Publicado: (2009)

Eye-Tracking for Clinical Ophthalmology with Virtual Reality (VR): A Case Study of the HTC Vive Pro Eye’s Usability
por: Sipatchin, Alexandra, et al.
Publicado: (2021)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells
por: Moghadasi, Seyed Arad, et al.
Publicado: (2022)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers
por: Garrido-Giménez, Carmen, et al.
Publicado: (2023)

Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment
por: Jiang, Zhidong, et al.
Publicado: (2023)

Fine mapping and identification of candidate genes for the peach powdery mildew resistance gene Vr3
por: Marimon, Neus, et al.
Publicado: (2020)

Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, M(pro) and PL(pro) of SARS-CoV-2: Protein–Protein Interactions, Dynamics Simulations and Free Energy Calculations
por: Naidoo, Devashan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e3iv15nk2h0rv2m9gha6pmn38u